Global Atosiban

Atosiban Comprehensive Study by Type (Injection, Concentrate), Application (Suppression of Preterm Labour, Others), End User (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2028

Atosiban Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Atosiban Market?

Over recent decades, the frequency of preterm birth in most Western countries seems to be increasing rather than decreasing, according to the research 24% or one four children born prematurely across the globe. Increasing incidences of preterm birth, various pregnancies, infections, and chronic conditions, for example, diabetes and hypertension among pregnant ladies are driving the development of the atosiban market. Atosiban is a potent stimulator of myometrial contractions and assumes a significant part in the inception of both term and preterm labor. It is used after assisted reproduction, preterm birth, and to halt premature labor due to its ability to decrease contractions and improve uterine receptivity by reducing intracytoplasmic calcium release and downregulate prostaglandin synthesis. As per the World Health Organization, consistently, an estimated 15 million infants are born preterm and this figure is rising step by step. Across 184 nations, the pace of preterm birth goes from 5% to 18% of babies born.

Highlights from Atosiban Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledFerring Pharmaceuticals (Switzerland), Sun Pharmaceutical Industries (India), Shanghai Soho-Yiming Pharmaceuticals Co., Ltd.(China), EVER NEURO PHARMA GMBH (Austria), Cayman Chemical (United States), Hemmo Pharmaceuticals Pvt Ltd (India), GlaxoSmithKline plc. (United Kingdom) and Xiamen Neore Pharmaceutical Technology Co., Ltd (China)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that China Players will contribute to the maximum growth of Global Atosiban market throughout the forecasted period.

Ferring Pharmaceuticals (Switzerland), Sun Pharmaceutical Industries (India), Shanghai Soho-Yiming Pharmaceuticals Co., Ltd.(China), EVER NEURO PHARMA GMBH (Austria), Cayman Chemical (United States), Hemmo Pharmaceuticals Pvt Ltd (India), GlaxoSmithKline plc. (United Kingdom) and Xiamen Neore Pharmaceutical Technology Co., Ltd (China) are some of the key players profiled in the study.

Atosiban Market Segmentation:
ScopeSub-Segments
Application / End UserSuppression of Preterm Labour and Others
TypeInjection and Concentrate
End UserHospitals,Clinics,Others


On the basis of geography, the market of Atosiban has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Global efforts to further reduce child mortality demand urgent action to address preterm birth

Market Growth Drivers:
Rise in the incidence of multiple pregnancies, infections, and chronic conditions and High incidence of the complications in birth occuring

Challenges:
Lack of hospital facilities

Restraints:
Adverse effect of the atosiban such as Nausea and Drugs registered for Atosiban are restricted

Opportunities:
Increasing incidences of preterm birth and Emerging demand from the countries such as India, China owing to highest preterm birth burden

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Atosiban Manufacturer, Government Regulatory and Research Organizations and End Use Industry

Market Leaders & Development Strategies
In January 2023, Sun Pharma acquires three brands of Mumbai-based Aksigen Hospital Care to strengthen its anti-inflammatory portfolio Sun Pharma's strategy has been a mix of organic and inorganic growth. We are also launching new drugs for domestic and global markets.
In March 2021, Piramal Pharma Solutions (PPS) acquired Hemmo Pharmaceuticals Pvt. Ltd was acquired for 775 million rupees (about 775 million won), the two companies said in a joint statement on Wednesday. PPS is the Contract Development and Manufacturing Organization (CDMO) of Piramal Pharma Ltd (PPL). The acquisition moves PPS into the development and manufacture of peptide-active pharmaceutical ingredients (APIs) that complement its existing service offerings.


Report Objectives / Segmentation Covered

By Type
  • Injection
  • Concentrate
By Application
  • Suppression of Preterm Labour
  • Others
By End User
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in the incidence of multiple pregnancies, infections, and chronic conditions
      • 3.2.2. High incidence of the complications in birth occuring
    • 3.3. Market Challenges
      • 3.3.1. Lack of hospital facilities
    • 3.4. Market Trends
      • 3.4.1. Global efforts to further reduce child mortality demand urgent action to address preterm birth
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Atosiban, by Type, Application, End User and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Atosiban (Value)
      • 5.2.1. Global Atosiban by: Type (Value)
        • 5.2.1.1. Injection
        • 5.2.1.2. Concentrate
      • 5.2.2. Global Atosiban by: Application (Value)
        • 5.2.2.1. Suppression of Preterm Labour
        • 5.2.2.2. Others
      • 5.2.3. Global Atosiban by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Atosiban Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Atosiban (Volume)
      • 5.3.1. Global Atosiban by: Type (Volume)
        • 5.3.1.1. Injection
        • 5.3.1.2. Concentrate
      • 5.3.2. Global Atosiban by: Application (Volume)
        • 5.3.2.1. Suppression of Preterm Labour
        • 5.3.2.2. Others
      • 5.3.3. Global Atosiban by: End User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Others
      • 5.3.4. Global Atosiban Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Atosiban (Price)
      • 5.4.1. Global Atosiban by: Type (Price)
  • 6. Atosiban: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ferring Pharmaceuticals (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sun Pharmaceutical Industries (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Shanghai Soho-Yiming Pharmaceuticals Co., Ltd.(China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. EVER NEURO PHARMA GMBH (Austria)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cayman Chemical (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hemmo Pharmaceuticals Pvt Ltd (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Xiamen Neore Pharmaceutical Technology Co., Ltd (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Atosiban Sale, by Type, Application, End User and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Atosiban (Value)
      • 7.2.1. Global Atosiban by: Type (Value)
        • 7.2.1.1. Injection
        • 7.2.1.2. Concentrate
      • 7.2.2. Global Atosiban by: Application (Value)
        • 7.2.2.1. Suppression of Preterm Labour
        • 7.2.2.2. Others
      • 7.2.3. Global Atosiban by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Atosiban Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Atosiban (Volume)
      • 7.3.1. Global Atosiban by: Type (Volume)
        • 7.3.1.1. Injection
        • 7.3.1.2. Concentrate
      • 7.3.2. Global Atosiban by: Application (Volume)
        • 7.3.2.1. Suppression of Preterm Labour
        • 7.3.2.2. Others
      • 7.3.3. Global Atosiban by: End User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Others
      • 7.3.4. Global Atosiban Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Atosiban (Price)
      • 7.4.1. Global Atosiban by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Atosiban: by Type(USD Million)
  • Table 2. Atosiban Injection , by Region USD Million (2017-2022)
  • Table 3. Atosiban Concentrate , by Region USD Million (2017-2022)
  • Table 4. Atosiban: by Application(USD Million)
  • Table 5. Atosiban Suppression of Preterm Labour , by Region USD Million (2017-2022)
  • Table 6. Atosiban Others , by Region USD Million (2017-2022)
  • Table 7. Atosiban: by End User(USD Million)
  • Table 8. Atosiban Hospitals , by Region USD Million (2017-2022)
  • Table 9. Atosiban Clinics , by Region USD Million (2017-2022)
  • Table 10. Atosiban Others , by Region USD Million (2017-2022)
  • Table 11. South America Atosiban, by Country USD Million (2017-2022)
  • Table 12. South America Atosiban, by Type USD Million (2017-2022)
  • Table 13. South America Atosiban, by Application USD Million (2017-2022)
  • Table 14. South America Atosiban, by End User USD Million (2017-2022)
  • Table 15. Brazil Atosiban, by Type USD Million (2017-2022)
  • Table 16. Brazil Atosiban, by Application USD Million (2017-2022)
  • Table 17. Brazil Atosiban, by End User USD Million (2017-2022)
  • Table 18. Argentina Atosiban, by Type USD Million (2017-2022)
  • Table 19. Argentina Atosiban, by Application USD Million (2017-2022)
  • Table 20. Argentina Atosiban, by End User USD Million (2017-2022)
  • Table 21. Rest of South America Atosiban, by Type USD Million (2017-2022)
  • Table 22. Rest of South America Atosiban, by Application USD Million (2017-2022)
  • Table 23. Rest of South America Atosiban, by End User USD Million (2017-2022)
  • Table 24. Asia Pacific Atosiban, by Country USD Million (2017-2022)
  • Table 25. Asia Pacific Atosiban, by Type USD Million (2017-2022)
  • Table 26. Asia Pacific Atosiban, by Application USD Million (2017-2022)
  • Table 27. Asia Pacific Atosiban, by End User USD Million (2017-2022)
  • Table 28. China Atosiban, by Type USD Million (2017-2022)
  • Table 29. China Atosiban, by Application USD Million (2017-2022)
  • Table 30. China Atosiban, by End User USD Million (2017-2022)
  • Table 31. Japan Atosiban, by Type USD Million (2017-2022)
  • Table 32. Japan Atosiban, by Application USD Million (2017-2022)
  • Table 33. Japan Atosiban, by End User USD Million (2017-2022)
  • Table 34. India Atosiban, by Type USD Million (2017-2022)
  • Table 35. India Atosiban, by Application USD Million (2017-2022)
  • Table 36. India Atosiban, by End User USD Million (2017-2022)
  • Table 37. South Korea Atosiban, by Type USD Million (2017-2022)
  • Table 38. South Korea Atosiban, by Application USD Million (2017-2022)
  • Table 39. South Korea Atosiban, by End User USD Million (2017-2022)
  • Table 40. Taiwan Atosiban, by Type USD Million (2017-2022)
  • Table 41. Taiwan Atosiban, by Application USD Million (2017-2022)
  • Table 42. Taiwan Atosiban, by End User USD Million (2017-2022)
  • Table 43. Australia Atosiban, by Type USD Million (2017-2022)
  • Table 44. Australia Atosiban, by Application USD Million (2017-2022)
  • Table 45. Australia Atosiban, by End User USD Million (2017-2022)
  • Table 46. Rest of Asia-Pacific Atosiban, by Type USD Million (2017-2022)
  • Table 47. Rest of Asia-Pacific Atosiban, by Application USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Atosiban, by End User USD Million (2017-2022)
  • Table 49. Europe Atosiban, by Country USD Million (2017-2022)
  • Table 50. Europe Atosiban, by Type USD Million (2017-2022)
  • Table 51. Europe Atosiban, by Application USD Million (2017-2022)
  • Table 52. Europe Atosiban, by End User USD Million (2017-2022)
  • Table 53. Germany Atosiban, by Type USD Million (2017-2022)
  • Table 54. Germany Atosiban, by Application USD Million (2017-2022)
  • Table 55. Germany Atosiban, by End User USD Million (2017-2022)
  • Table 56. France Atosiban, by Type USD Million (2017-2022)
  • Table 57. France Atosiban, by Application USD Million (2017-2022)
  • Table 58. France Atosiban, by End User USD Million (2017-2022)
  • Table 59. Italy Atosiban, by Type USD Million (2017-2022)
  • Table 60. Italy Atosiban, by Application USD Million (2017-2022)
  • Table 61. Italy Atosiban, by End User USD Million (2017-2022)
  • Table 62. United Kingdom Atosiban, by Type USD Million (2017-2022)
  • Table 63. United Kingdom Atosiban, by Application USD Million (2017-2022)
  • Table 64. United Kingdom Atosiban, by End User USD Million (2017-2022)
  • Table 65. Netherlands Atosiban, by Type USD Million (2017-2022)
  • Table 66. Netherlands Atosiban, by Application USD Million (2017-2022)
  • Table 67. Netherlands Atosiban, by End User USD Million (2017-2022)
  • Table 68. Rest of Europe Atosiban, by Type USD Million (2017-2022)
  • Table 69. Rest of Europe Atosiban, by Application USD Million (2017-2022)
  • Table 70. Rest of Europe Atosiban, by End User USD Million (2017-2022)
  • Table 71. MEA Atosiban, by Country USD Million (2017-2022)
  • Table 72. MEA Atosiban, by Type USD Million (2017-2022)
  • Table 73. MEA Atosiban, by Application USD Million (2017-2022)
  • Table 74. MEA Atosiban, by End User USD Million (2017-2022)
  • Table 75. Middle East Atosiban, by Type USD Million (2017-2022)
  • Table 76. Middle East Atosiban, by Application USD Million (2017-2022)
  • Table 77. Middle East Atosiban, by End User USD Million (2017-2022)
  • Table 78. Africa Atosiban, by Type USD Million (2017-2022)
  • Table 79. Africa Atosiban, by Application USD Million (2017-2022)
  • Table 80. Africa Atosiban, by End User USD Million (2017-2022)
  • Table 81. North America Atosiban, by Country USD Million (2017-2022)
  • Table 82. North America Atosiban, by Type USD Million (2017-2022)
  • Table 83. North America Atosiban, by Application USD Million (2017-2022)
  • Table 84. North America Atosiban, by End User USD Million (2017-2022)
  • Table 85. United States Atosiban, by Type USD Million (2017-2022)
  • Table 86. United States Atosiban, by Application USD Million (2017-2022)
  • Table 87. United States Atosiban, by End User USD Million (2017-2022)
  • Table 88. Canada Atosiban, by Type USD Million (2017-2022)
  • Table 89. Canada Atosiban, by Application USD Million (2017-2022)
  • Table 90. Canada Atosiban, by End User USD Million (2017-2022)
  • Table 91. Mexico Atosiban, by Type USD Million (2017-2022)
  • Table 92. Mexico Atosiban, by Application USD Million (2017-2022)
  • Table 93. Mexico Atosiban, by End User USD Million (2017-2022)
  • Table 94. Atosiban Sales: by Type(K Tons)
  • Table 95. Atosiban Sales Injection , by Region K Tons (2017-2022)
  • Table 96. Atosiban Sales Concentrate , by Region K Tons (2017-2022)
  • Table 97. Atosiban Sales: by Application(K Tons)
  • Table 98. Atosiban Sales Suppression of Preterm Labour , by Region K Tons (2017-2022)
  • Table 99. Atosiban Sales Others , by Region K Tons (2017-2022)
  • Table 100. Atosiban Sales: by End User(K Tons)
  • Table 101. Atosiban Sales Hospitals , by Region K Tons (2017-2022)
  • Table 102. Atosiban Sales Clinics , by Region K Tons (2017-2022)
  • Table 103. Atosiban Sales Others , by Region K Tons (2017-2022)
  • Table 104. South America Atosiban Sales, by Country K Tons (2017-2022)
  • Table 105. South America Atosiban Sales, by Type K Tons (2017-2022)
  • Table 106. South America Atosiban Sales, by Application K Tons (2017-2022)
  • Table 107. South America Atosiban Sales, by End User K Tons (2017-2022)
  • Table 108. Brazil Atosiban Sales, by Type K Tons (2017-2022)
  • Table 109. Brazil Atosiban Sales, by Application K Tons (2017-2022)
  • Table 110. Brazil Atosiban Sales, by End User K Tons (2017-2022)
  • Table 111. Argentina Atosiban Sales, by Type K Tons (2017-2022)
  • Table 112. Argentina Atosiban Sales, by Application K Tons (2017-2022)
  • Table 113. Argentina Atosiban Sales, by End User K Tons (2017-2022)
  • Table 114. Rest of South America Atosiban Sales, by Type K Tons (2017-2022)
  • Table 115. Rest of South America Atosiban Sales, by Application K Tons (2017-2022)
  • Table 116. Rest of South America Atosiban Sales, by End User K Tons (2017-2022)
  • Table 117. Asia Pacific Atosiban Sales, by Country K Tons (2017-2022)
  • Table 118. Asia Pacific Atosiban Sales, by Type K Tons (2017-2022)
  • Table 119. Asia Pacific Atosiban Sales, by Application K Tons (2017-2022)
  • Table 120. Asia Pacific Atosiban Sales, by End User K Tons (2017-2022)
  • Table 121. China Atosiban Sales, by Type K Tons (2017-2022)
  • Table 122. China Atosiban Sales, by Application K Tons (2017-2022)
  • Table 123. China Atosiban Sales, by End User K Tons (2017-2022)
  • Table 124. Japan Atosiban Sales, by Type K Tons (2017-2022)
  • Table 125. Japan Atosiban Sales, by Application K Tons (2017-2022)
  • Table 126. Japan Atosiban Sales, by End User K Tons (2017-2022)
  • Table 127. India Atosiban Sales, by Type K Tons (2017-2022)
  • Table 128. India Atosiban Sales, by Application K Tons (2017-2022)
  • Table 129. India Atosiban Sales, by End User K Tons (2017-2022)
  • Table 130. South Korea Atosiban Sales, by Type K Tons (2017-2022)
  • Table 131. South Korea Atosiban Sales, by Application K Tons (2017-2022)
  • Table 132. South Korea Atosiban Sales, by End User K Tons (2017-2022)
  • Table 133. Taiwan Atosiban Sales, by Type K Tons (2017-2022)
  • Table 134. Taiwan Atosiban Sales, by Application K Tons (2017-2022)
  • Table 135. Taiwan Atosiban Sales, by End User K Tons (2017-2022)
  • Table 136. Australia Atosiban Sales, by Type K Tons (2017-2022)
  • Table 137. Australia Atosiban Sales, by Application K Tons (2017-2022)
  • Table 138. Australia Atosiban Sales, by End User K Tons (2017-2022)
  • Table 139. Rest of Asia-Pacific Atosiban Sales, by Type K Tons (2017-2022)
  • Table 140. Rest of Asia-Pacific Atosiban Sales, by Application K Tons (2017-2022)
  • Table 141. Rest of Asia-Pacific Atosiban Sales, by End User K Tons (2017-2022)
  • Table 142. Europe Atosiban Sales, by Country K Tons (2017-2022)
  • Table 143. Europe Atosiban Sales, by Type K Tons (2017-2022)
  • Table 144. Europe Atosiban Sales, by Application K Tons (2017-2022)
  • Table 145. Europe Atosiban Sales, by End User K Tons (2017-2022)
  • Table 146. Germany Atosiban Sales, by Type K Tons (2017-2022)
  • Table 147. Germany Atosiban Sales, by Application K Tons (2017-2022)
  • Table 148. Germany Atosiban Sales, by End User K Tons (2017-2022)
  • Table 149. France Atosiban Sales, by Type K Tons (2017-2022)
  • Table 150. France Atosiban Sales, by Application K Tons (2017-2022)
  • Table 151. France Atosiban Sales, by End User K Tons (2017-2022)
  • Table 152. Italy Atosiban Sales, by Type K Tons (2017-2022)
  • Table 153. Italy Atosiban Sales, by Application K Tons (2017-2022)
  • Table 154. Italy Atosiban Sales, by End User K Tons (2017-2022)
  • Table 155. United Kingdom Atosiban Sales, by Type K Tons (2017-2022)
  • Table 156. United Kingdom Atosiban Sales, by Application K Tons (2017-2022)
  • Table 157. United Kingdom Atosiban Sales, by End User K Tons (2017-2022)
  • Table 158. Netherlands Atosiban Sales, by Type K Tons (2017-2022)
  • Table 159. Netherlands Atosiban Sales, by Application K Tons (2017-2022)
  • Table 160. Netherlands Atosiban Sales, by End User K Tons (2017-2022)
  • Table 161. Rest of Europe Atosiban Sales, by Type K Tons (2017-2022)
  • Table 162. Rest of Europe Atosiban Sales, by Application K Tons (2017-2022)
  • Table 163. Rest of Europe Atosiban Sales, by End User K Tons (2017-2022)
  • Table 164. MEA Atosiban Sales, by Country K Tons (2017-2022)
  • Table 165. MEA Atosiban Sales, by Type K Tons (2017-2022)
  • Table 166. MEA Atosiban Sales, by Application K Tons (2017-2022)
  • Table 167. MEA Atosiban Sales, by End User K Tons (2017-2022)
  • Table 168. Middle East Atosiban Sales, by Type K Tons (2017-2022)
  • Table 169. Middle East Atosiban Sales, by Application K Tons (2017-2022)
  • Table 170. Middle East Atosiban Sales, by End User K Tons (2017-2022)
  • Table 171. Africa Atosiban Sales, by Type K Tons (2017-2022)
  • Table 172. Africa Atosiban Sales, by Application K Tons (2017-2022)
  • Table 173. Africa Atosiban Sales, by End User K Tons (2017-2022)
  • Table 174. North America Atosiban Sales, by Country K Tons (2017-2022)
  • Table 175. North America Atosiban Sales, by Type K Tons (2017-2022)
  • Table 176. North America Atosiban Sales, by Application K Tons (2017-2022)
  • Table 177. North America Atosiban Sales, by End User K Tons (2017-2022)
  • Table 178. United States Atosiban Sales, by Type K Tons (2017-2022)
  • Table 179. United States Atosiban Sales, by Application K Tons (2017-2022)
  • Table 180. United States Atosiban Sales, by End User K Tons (2017-2022)
  • Table 181. Canada Atosiban Sales, by Type K Tons (2017-2022)
  • Table 182. Canada Atosiban Sales, by Application K Tons (2017-2022)
  • Table 183. Canada Atosiban Sales, by End User K Tons (2017-2022)
  • Table 184. Mexico Atosiban Sales, by Type K Tons (2017-2022)
  • Table 185. Mexico Atosiban Sales, by Application K Tons (2017-2022)
  • Table 186. Mexico Atosiban Sales, by End User K Tons (2017-2022)
  • Table 187. Atosiban: by Type(USD/Units)
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Atosiban: by Type(USD Million)
  • Table 197. Atosiban Injection , by Region USD Million (2023-2028)
  • Table 198. Atosiban Concentrate , by Region USD Million (2023-2028)
  • Table 199. Atosiban: by Application(USD Million)
  • Table 200. Atosiban Suppression of Preterm Labour , by Region USD Million (2023-2028)
  • Table 201. Atosiban Others , by Region USD Million (2023-2028)
  • Table 202. Atosiban: by End User(USD Million)
  • Table 203. Atosiban Hospitals , by Region USD Million (2023-2028)
  • Table 204. Atosiban Clinics , by Region USD Million (2023-2028)
  • Table 205. Atosiban Others , by Region USD Million (2023-2028)
  • Table 206. South America Atosiban, by Country USD Million (2023-2028)
  • Table 207. South America Atosiban, by Type USD Million (2023-2028)
  • Table 208. South America Atosiban, by Application USD Million (2023-2028)
  • Table 209. South America Atosiban, by End User USD Million (2023-2028)
  • Table 210. Brazil Atosiban, by Type USD Million (2023-2028)
  • Table 211. Brazil Atosiban, by Application USD Million (2023-2028)
  • Table 212. Brazil Atosiban, by End User USD Million (2023-2028)
  • Table 213. Argentina Atosiban, by Type USD Million (2023-2028)
  • Table 214. Argentina Atosiban, by Application USD Million (2023-2028)
  • Table 215. Argentina Atosiban, by End User USD Million (2023-2028)
  • Table 216. Rest of South America Atosiban, by Type USD Million (2023-2028)
  • Table 217. Rest of South America Atosiban, by Application USD Million (2023-2028)
  • Table 218. Rest of South America Atosiban, by End User USD Million (2023-2028)
  • Table 219. Asia Pacific Atosiban, by Country USD Million (2023-2028)
  • Table 220. Asia Pacific Atosiban, by Type USD Million (2023-2028)
  • Table 221. Asia Pacific Atosiban, by Application USD Million (2023-2028)
  • Table 222. Asia Pacific Atosiban, by End User USD Million (2023-2028)
  • Table 223. China Atosiban, by Type USD Million (2023-2028)
  • Table 224. China Atosiban, by Application USD Million (2023-2028)
  • Table 225. China Atosiban, by End User USD Million (2023-2028)
  • Table 226. Japan Atosiban, by Type USD Million (2023-2028)
  • Table 227. Japan Atosiban, by Application USD Million (2023-2028)
  • Table 228. Japan Atosiban, by End User USD Million (2023-2028)
  • Table 229. India Atosiban, by Type USD Million (2023-2028)
  • Table 230. India Atosiban, by Application USD Million (2023-2028)
  • Table 231. India Atosiban, by End User USD Million (2023-2028)
  • Table 232. South Korea Atosiban, by Type USD Million (2023-2028)
  • Table 233. South Korea Atosiban, by Application USD Million (2023-2028)
  • Table 234. South Korea Atosiban, by End User USD Million (2023-2028)
  • Table 235. Taiwan Atosiban, by Type USD Million (2023-2028)
  • Table 236. Taiwan Atosiban, by Application USD Million (2023-2028)
  • Table 237. Taiwan Atosiban, by End User USD Million (2023-2028)
  • Table 238. Australia Atosiban, by Type USD Million (2023-2028)
  • Table 239. Australia Atosiban, by Application USD Million (2023-2028)
  • Table 240. Australia Atosiban, by End User USD Million (2023-2028)
  • Table 241. Rest of Asia-Pacific Atosiban, by Type USD Million (2023-2028)
  • Table 242. Rest of Asia-Pacific Atosiban, by Application USD Million (2023-2028)
  • Table 243. Rest of Asia-Pacific Atosiban, by End User USD Million (2023-2028)
  • Table 244. Europe Atosiban, by Country USD Million (2023-2028)
  • Table 245. Europe Atosiban, by Type USD Million (2023-2028)
  • Table 246. Europe Atosiban, by Application USD Million (2023-2028)
  • Table 247. Europe Atosiban, by End User USD Million (2023-2028)
  • Table 248. Germany Atosiban, by Type USD Million (2023-2028)
  • Table 249. Germany Atosiban, by Application USD Million (2023-2028)
  • Table 250. Germany Atosiban, by End User USD Million (2023-2028)
  • Table 251. France Atosiban, by Type USD Million (2023-2028)
  • Table 252. France Atosiban, by Application USD Million (2023-2028)
  • Table 253. France Atosiban, by End User USD Million (2023-2028)
  • Table 254. Italy Atosiban, by Type USD Million (2023-2028)
  • Table 255. Italy Atosiban, by Application USD Million (2023-2028)
  • Table 256. Italy Atosiban, by End User USD Million (2023-2028)
  • Table 257. United Kingdom Atosiban, by Type USD Million (2023-2028)
  • Table 258. United Kingdom Atosiban, by Application USD Million (2023-2028)
  • Table 259. United Kingdom Atosiban, by End User USD Million (2023-2028)
  • Table 260. Netherlands Atosiban, by Type USD Million (2023-2028)
  • Table 261. Netherlands Atosiban, by Application USD Million (2023-2028)
  • Table 262. Netherlands Atosiban, by End User USD Million (2023-2028)
  • Table 263. Rest of Europe Atosiban, by Type USD Million (2023-2028)
  • Table 264. Rest of Europe Atosiban, by Application USD Million (2023-2028)
  • Table 265. Rest of Europe Atosiban, by End User USD Million (2023-2028)
  • Table 266. MEA Atosiban, by Country USD Million (2023-2028)
  • Table 267. MEA Atosiban, by Type USD Million (2023-2028)
  • Table 268. MEA Atosiban, by Application USD Million (2023-2028)
  • Table 269. MEA Atosiban, by End User USD Million (2023-2028)
  • Table 270. Middle East Atosiban, by Type USD Million (2023-2028)
  • Table 271. Middle East Atosiban, by Application USD Million (2023-2028)
  • Table 272. Middle East Atosiban, by End User USD Million (2023-2028)
  • Table 273. Africa Atosiban, by Type USD Million (2023-2028)
  • Table 274. Africa Atosiban, by Application USD Million (2023-2028)
  • Table 275. Africa Atosiban, by End User USD Million (2023-2028)
  • Table 276. North America Atosiban, by Country USD Million (2023-2028)
  • Table 277. North America Atosiban, by Type USD Million (2023-2028)
  • Table 278. North America Atosiban, by Application USD Million (2023-2028)
  • Table 279. North America Atosiban, by End User USD Million (2023-2028)
  • Table 280. United States Atosiban, by Type USD Million (2023-2028)
  • Table 281. United States Atosiban, by Application USD Million (2023-2028)
  • Table 282. United States Atosiban, by End User USD Million (2023-2028)
  • Table 283. Canada Atosiban, by Type USD Million (2023-2028)
  • Table 284. Canada Atosiban, by Application USD Million (2023-2028)
  • Table 285. Canada Atosiban, by End User USD Million (2023-2028)
  • Table 286. Mexico Atosiban, by Type USD Million (2023-2028)
  • Table 287. Mexico Atosiban, by Application USD Million (2023-2028)
  • Table 288. Mexico Atosiban, by End User USD Million (2023-2028)
  • Table 289. Atosiban Sales: by Type(K Tons)
  • Table 290. Atosiban Sales Injection , by Region K Tons (2023-2028)
  • Table 291. Atosiban Sales Concentrate , by Region K Tons (2023-2028)
  • Table 292. Atosiban Sales: by Application(K Tons)
  • Table 293. Atosiban Sales Suppression of Preterm Labour , by Region K Tons (2023-2028)
  • Table 294. Atosiban Sales Others , by Region K Tons (2023-2028)
  • Table 295. Atosiban Sales: by End User(K Tons)
  • Table 296. Atosiban Sales Hospitals , by Region K Tons (2023-2028)
  • Table 297. Atosiban Sales Clinics , by Region K Tons (2023-2028)
  • Table 298. Atosiban Sales Others , by Region K Tons (2023-2028)
  • Table 299. South America Atosiban Sales, by Country K Tons (2023-2028)
  • Table 300. South America Atosiban Sales, by Type K Tons (2023-2028)
  • Table 301. South America Atosiban Sales, by Application K Tons (2023-2028)
  • Table 302. South America Atosiban Sales, by End User K Tons (2023-2028)
  • Table 303. Brazil Atosiban Sales, by Type K Tons (2023-2028)
  • Table 304. Brazil Atosiban Sales, by Application K Tons (2023-2028)
  • Table 305. Brazil Atosiban Sales, by End User K Tons (2023-2028)
  • Table 306. Argentina Atosiban Sales, by Type K Tons (2023-2028)
  • Table 307. Argentina Atosiban Sales, by Application K Tons (2023-2028)
  • Table 308. Argentina Atosiban Sales, by End User K Tons (2023-2028)
  • Table 309. Rest of South America Atosiban Sales, by Type K Tons (2023-2028)
  • Table 310. Rest of South America Atosiban Sales, by Application K Tons (2023-2028)
  • Table 311. Rest of South America Atosiban Sales, by End User K Tons (2023-2028)
  • Table 312. Asia Pacific Atosiban Sales, by Country K Tons (2023-2028)
  • Table 313. Asia Pacific Atosiban Sales, by Type K Tons (2023-2028)
  • Table 314. Asia Pacific Atosiban Sales, by Application K Tons (2023-2028)
  • Table 315. Asia Pacific Atosiban Sales, by End User K Tons (2023-2028)
  • Table 316. China Atosiban Sales, by Type K Tons (2023-2028)
  • Table 317. China Atosiban Sales, by Application K Tons (2023-2028)
  • Table 318. China Atosiban Sales, by End User K Tons (2023-2028)
  • Table 319. Japan Atosiban Sales, by Type K Tons (2023-2028)
  • Table 320. Japan Atosiban Sales, by Application K Tons (2023-2028)
  • Table 321. Japan Atosiban Sales, by End User K Tons (2023-2028)
  • Table 322. India Atosiban Sales, by Type K Tons (2023-2028)
  • Table 323. India Atosiban Sales, by Application K Tons (2023-2028)
  • Table 324. India Atosiban Sales, by End User K Tons (2023-2028)
  • Table 325. South Korea Atosiban Sales, by Type K Tons (2023-2028)
  • Table 326. South Korea Atosiban Sales, by Application K Tons (2023-2028)
  • Table 327. South Korea Atosiban Sales, by End User K Tons (2023-2028)
  • Table 328. Taiwan Atosiban Sales, by Type K Tons (2023-2028)
  • Table 329. Taiwan Atosiban Sales, by Application K Tons (2023-2028)
  • Table 330. Taiwan Atosiban Sales, by End User K Tons (2023-2028)
  • Table 331. Australia Atosiban Sales, by Type K Tons (2023-2028)
  • Table 332. Australia Atosiban Sales, by Application K Tons (2023-2028)
  • Table 333. Australia Atosiban Sales, by End User K Tons (2023-2028)
  • Table 334. Rest of Asia-Pacific Atosiban Sales, by Type K Tons (2023-2028)
  • Table 335. Rest of Asia-Pacific Atosiban Sales, by Application K Tons (2023-2028)
  • Table 336. Rest of Asia-Pacific Atosiban Sales, by End User K Tons (2023-2028)
  • Table 337. Europe Atosiban Sales, by Country K Tons (2023-2028)
  • Table 338. Europe Atosiban Sales, by Type K Tons (2023-2028)
  • Table 339. Europe Atosiban Sales, by Application K Tons (2023-2028)
  • Table 340. Europe Atosiban Sales, by End User K Tons (2023-2028)
  • Table 341. Germany Atosiban Sales, by Type K Tons (2023-2028)
  • Table 342. Germany Atosiban Sales, by Application K Tons (2023-2028)
  • Table 343. Germany Atosiban Sales, by End User K Tons (2023-2028)
  • Table 344. France Atosiban Sales, by Type K Tons (2023-2028)
  • Table 345. France Atosiban Sales, by Application K Tons (2023-2028)
  • Table 346. France Atosiban Sales, by End User K Tons (2023-2028)
  • Table 347. Italy Atosiban Sales, by Type K Tons (2023-2028)
  • Table 348. Italy Atosiban Sales, by Application K Tons (2023-2028)
  • Table 349. Italy Atosiban Sales, by End User K Tons (2023-2028)
  • Table 350. United Kingdom Atosiban Sales, by Type K Tons (2023-2028)
  • Table 351. United Kingdom Atosiban Sales, by Application K Tons (2023-2028)
  • Table 352. United Kingdom Atosiban Sales, by End User K Tons (2023-2028)
  • Table 353. Netherlands Atosiban Sales, by Type K Tons (2023-2028)
  • Table 354. Netherlands Atosiban Sales, by Application K Tons (2023-2028)
  • Table 355. Netherlands Atosiban Sales, by End User K Tons (2023-2028)
  • Table 356. Rest of Europe Atosiban Sales, by Type K Tons (2023-2028)
  • Table 357. Rest of Europe Atosiban Sales, by Application K Tons (2023-2028)
  • Table 358. Rest of Europe Atosiban Sales, by End User K Tons (2023-2028)
  • Table 359. MEA Atosiban Sales, by Country K Tons (2023-2028)
  • Table 360. MEA Atosiban Sales, by Type K Tons (2023-2028)
  • Table 361. MEA Atosiban Sales, by Application K Tons (2023-2028)
  • Table 362. MEA Atosiban Sales, by End User K Tons (2023-2028)
  • Table 363. Middle East Atosiban Sales, by Type K Tons (2023-2028)
  • Table 364. Middle East Atosiban Sales, by Application K Tons (2023-2028)
  • Table 365. Middle East Atosiban Sales, by End User K Tons (2023-2028)
  • Table 366. Africa Atosiban Sales, by Type K Tons (2023-2028)
  • Table 367. Africa Atosiban Sales, by Application K Tons (2023-2028)
  • Table 368. Africa Atosiban Sales, by End User K Tons (2023-2028)
  • Table 369. North America Atosiban Sales, by Country K Tons (2023-2028)
  • Table 370. North America Atosiban Sales, by Type K Tons (2023-2028)
  • Table 371. North America Atosiban Sales, by Application K Tons (2023-2028)
  • Table 372. North America Atosiban Sales, by End User K Tons (2023-2028)
  • Table 373. United States Atosiban Sales, by Type K Tons (2023-2028)
  • Table 374. United States Atosiban Sales, by Application K Tons (2023-2028)
  • Table 375. United States Atosiban Sales, by End User K Tons (2023-2028)
  • Table 376. Canada Atosiban Sales, by Type K Tons (2023-2028)
  • Table 377. Canada Atosiban Sales, by Application K Tons (2023-2028)
  • Table 378. Canada Atosiban Sales, by End User K Tons (2023-2028)
  • Table 379. Mexico Atosiban Sales, by Type K Tons (2023-2028)
  • Table 380. Mexico Atosiban Sales, by Application K Tons (2023-2028)
  • Table 381. Mexico Atosiban Sales, by End User K Tons (2023-2028)
  • Table 382. Atosiban: by Type(USD/Units)
  • Table 383. Research Programs/Design for This Report
  • Table 384. Key Data Information from Secondary Sources
  • Table 385. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Atosiban: by Type USD Million (2017-2022)
  • Figure 5. Global Atosiban: by Application USD Million (2017-2022)
  • Figure 6. Global Atosiban: by End User USD Million (2017-2022)
  • Figure 7. South America Atosiban Share (%), by Country
  • Figure 8. Asia Pacific Atosiban Share (%), by Country
  • Figure 9. Europe Atosiban Share (%), by Country
  • Figure 10. MEA Atosiban Share (%), by Country
  • Figure 11. North America Atosiban Share (%), by Country
  • Figure 12. Global Atosiban: by Type K Tons (2017-2022)
  • Figure 13. Global Atosiban: by Application K Tons (2017-2022)
  • Figure 14. Global Atosiban: by End User K Tons (2017-2022)
  • Figure 15. South America Atosiban Share (%), by Country
  • Figure 16. Asia Pacific Atosiban Share (%), by Country
  • Figure 17. Europe Atosiban Share (%), by Country
  • Figure 18. MEA Atosiban Share (%), by Country
  • Figure 19. North America Atosiban Share (%), by Country
  • Figure 20. Global Atosiban: by Type USD/Units (2017-2022)
  • Figure 21. Global Atosiban share by Players 2022 (%)
  • Figure 22. Global Atosiban share by Players (Top 3) 2022(%)
  • Figure 23. Global Atosiban share by Players (Top 5) 2022(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Ferring Pharmaceuticals (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Ferring Pharmaceuticals (Switzerland) Revenue: by Geography 2022
  • Figure 27. Sun Pharmaceutical Industries (India) Revenue, Net Income and Gross profit
  • Figure 28. Sun Pharmaceutical Industries (India) Revenue: by Geography 2022
  • Figure 29. Shanghai Soho-Yiming Pharmaceuticals Co., Ltd.(China) Revenue, Net Income and Gross profit
  • Figure 30. Shanghai Soho-Yiming Pharmaceuticals Co., Ltd.(China) Revenue: by Geography 2022
  • Figure 31. EVER NEURO PHARMA GMBH (Austria) Revenue, Net Income and Gross profit
  • Figure 32. EVER NEURO PHARMA GMBH (Austria) Revenue: by Geography 2022
  • Figure 33. Cayman Chemical (United States) Revenue, Net Income and Gross profit
  • Figure 34. Cayman Chemical (United States) Revenue: by Geography 2022
  • Figure 35. Hemmo Pharmaceuticals Pvt Ltd (India) Revenue, Net Income and Gross profit
  • Figure 36. Hemmo Pharmaceuticals Pvt Ltd (India) Revenue: by Geography 2022
  • Figure 37. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 39. Xiamen Neore Pharmaceutical Technology Co., Ltd (China) Revenue, Net Income and Gross profit
  • Figure 40. Xiamen Neore Pharmaceutical Technology Co., Ltd (China) Revenue: by Geography 2022
  • Figure 41. Global Atosiban: by Type USD Million (2023-2028)
  • Figure 42. Global Atosiban: by Application USD Million (2023-2028)
  • Figure 43. Global Atosiban: by End User USD Million (2023-2028)
  • Figure 44. South America Atosiban Share (%), by Country
  • Figure 45. Asia Pacific Atosiban Share (%), by Country
  • Figure 46. Europe Atosiban Share (%), by Country
  • Figure 47. MEA Atosiban Share (%), by Country
  • Figure 48. North America Atosiban Share (%), by Country
  • Figure 49. Global Atosiban: by Type K Tons (2023-2028)
  • Figure 50. Global Atosiban: by Application K Tons (2023-2028)
  • Figure 51. Global Atosiban: by End User K Tons (2023-2028)
  • Figure 52. South America Atosiban Share (%), by Country
  • Figure 53. Asia Pacific Atosiban Share (%), by Country
  • Figure 54. Europe Atosiban Share (%), by Country
  • Figure 55. MEA Atosiban Share (%), by Country
  • Figure 56. North America Atosiban Share (%), by Country
  • Figure 57. Global Atosiban: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Ferring Pharmaceuticals (Switzerland)
  • Sun Pharmaceutical Industries (India)
  • Shanghai Soho-Yiming Pharmaceuticals Co., Ltd.(China)
  • EVER NEURO PHARMA GMBH (Austria)
  • Cayman Chemical (United States)
  • Hemmo Pharmaceuticals Pvt Ltd (India)
  • GlaxoSmithKline plc. (United Kingdom)
  • Xiamen Neore Pharmaceutical Technology Co., Ltd (China)
Select User Access Type

Key Highlights of Report


May 2023 224 Pages 51 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Atosiban Quantitative research analysis
Global Atosiban Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rise in the incidence of multiple pregnancies, infections, and chronic conditions " is seen as one of major growth factors of Atosiban Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Atosiban market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Atosiban Report?

Have a Query? Click Here

Other Related Reports

Pathogen Identification and Treatment Comprehensive Study by Type (Denaturation, Annealing, Amplification, Detection), Application (Biodefense, Animal Health Care, Food Safety, Diagnostics, Pathology...
$ 3350
Pulmonary Surfactant Comprehensive Study by Type (Synthetic Pulmonary Surfactants, Animal Derived Surfactants), Application (Hospital, Laboratory, Others), End User (Adults, Children) Players and Reg...
$ 3500
Cancer Supportive Care Drugs Comprehensive Study by Application (Chemotherapy Therapy, Radiation Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies), Cance...
$ 3750
Botanical and Plant Derived Drugs Comprehensive Study by Type (Tablets, Capsules, Pills, Injections), Application (Central Nervous System, Cardiovascular Diseases, Infectious Diseases, Respiratory Di...
$ 3750
Ashwagandha Extract Comprehensive Study by Application (Sports Nutrition, Food & Beverages, Dietary Supplements, Other), Source (Root, Leaves, Others), Extract Percentage (Ashwagandha Extract 1.5%, ...
$ 3650
Fosfomycin Sodium Comprehensive Study by Type (Tablets, Injection), Application (Common Urinary Tract Infection, Postoperative Urinary Tract Infection, Preoperative Prevention of Urinary Tract Infect...
$ 3650